BALTIMORE, May 19, 2011 /PRNewswire/ — BD Diagnostics, a
segment of BD (Becton, Dickinson and Company) (NYSE:
BDX), today announced the U.S. launch of the BD MAX™ for
use as an open system.
BD MAX is the first and only fully automated, bench-top
molecular system designed to perform a broad range of molecular
tests. This includes in vitro diagnostic (IVD) assays, but
also user-defined protocols and life science research applications.
The BD MAX System gives clinical laboratory professionals new
ability to help their institutions respond to emerging threats,
such as new strains of deadly drug-resistant bacteria or
respiratory illnesses.
“Saving a patient’s life often hinges upon clinicians’ access to
rapid, accurate and actionable diagnostic information, especially
in the case of an emerging infectious disease,” said Tom Polen,
President of BD Diagnostics – Diagnostic Systems. “The BD MAX
System empowers laboratories to provide this critical information
by giving them the capability to automate and standardize their
unique protocols on a state-of-the-art platform. We aim for the BD
MAX System to become an indispensible tool in the laboratory that
is equivalent to a smartphone.”
According to Polen, BD intends a steady stream of announcements
regarding agreements with best-in-class IVD assay developers to
bring new tests to the BD MAX System for a broad range of disease
categories. “When a lab expresses a need to detect a specific
organism or emerging disease, we want the BD MAX System to be a
solution,” said Polen.
Earlier this month, BD announced the collaboration with
Diagenode to develop seven initial assays for the BD MAX
System. These assays will include a panel for dia
‘/>”/>
